RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall

Dr. Reddy’s fiscal Q2 2027 earnings were 12 cents per ADS versus 16 cents expected, while revenue fell 1.5% year over year to $905 million, missing the $981 million estimate. North American generics revenue declined 23% amid lower lenalidomide sales, and gross margin contracted 254 basis points to 52.1%; emerging-markets and India revenue rose 24% and 17%, respectively. The company reported new biosimilar approvals and product launches, while its shares were down 5.9% year to date versus 7.7% growth for the industry.

Analysis

The key issue is earnings quality, not the headline miss: North American lenalidomide weakness has exposed how much near-term margin performance depends on a product-specific revenue stream, while growth elsewhere is not yet offsetting that mix drag and higher operating/input costs. Double-digit growth in the ex-lenalidomide base is encouraging, but without its revenue contribution and incremental profitability, it does not establish that replacement launches can restore consolidated margins. PSAI softness adds a separate warning that this is not solely a North America timing issue.

Over the next 1–3 months, supply validation for generic semaglutide and the Dec. 22 abatacept FDA action date are identifiable catalysts, but neither should be capitalized as earnings until timing and commercial uptake are confirmed. Over 6–18 months, biosimilars and complex generics could improve the portfolio mix; meanwhile, freight and input-cost inflation could delay any margin recovery. Emerging-market growth is less clean than the headline rate suggests because currency, acquisitions and pricing contributed.

Contrarian point: the operating base may be healthier than the consolidated print implies, so an indiscriminate short risks being squeezed by launches or a lenalidomide comparison easing. But partnership announcements involving Gilead Sciences, Takeda and Fresenius Kabi do not establish material near-term economics for those partners. The evidence supports caution on RDY, not a high-conviction sector read-through.

Key Decisions for Investors

• Underweight RDY rather than initiate an unhedged short immediately. Reassess after the next update: sustained weakness in North America excluding lenalidomide, or failure of gross margin to stabilize, would strengthen the downside case; demonstrable margin recovery would falsify it.
• Treat generic semaglutide resupply as a watch item, not a valuation catalyst yet. Verify successful validation and actual supply resumption in November; any delay or further quality issue would extend the earnings-risk window.
• Track the Dec. 22 FDA action on abatacept as a 1–3 month catalyst, but separate approval from launch economics. A delay or adverse outcome weakens the medium-term pipeline thesis; approval alone is not sufficient evidence of material earnings contribution.
• Do not trade GILD, TAK or FRE on the collaboration mentions alone. Seek disclosed commercial terms or measurable revenue contribution before assigning a partner-level earnings effect.